BillionToOne, Inc. Class A (BLLN)
NASDAQ:BLLN
Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$77.00
--
Market closed
$77.00
--
Day’s Range― - ―
52-Week Range$61.96 - $138.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)813.03K
Market Cap
$4.65B
Enterprise Value$4.16B
Total Cash (Recent Filing)$537.45M
Total Debt (Recent Filing)$144.19M
Price to Earnings (P/E)184.3
Beta1.32
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding41,442,833
10 Day Avg. Volume847,558
30 Day Avg. Volume813,032
Financial Highlights & Ratios
PEG Ratio-4.71
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue11.73
Enterprise Value/Gross Profit16.67
Enterprise Value/Ebitda101.78
Forecast
1Y Price Target
$123.33Price Target Upside60.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.98
Revenue Forecast (FY)$454.09M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Margin InflectionAn 84% YoY revenue surge with 73% gross margin and GAAP operating profitability demonstrates durable demand, pricing power (ASP lifts) and improved unit economics. These structural improvements support sustainable operating leverage if volume and ASP trends persist over several quarters.
Strong Balance Sheet And Positive Cash GenerationA large cash balance plus positive cash generation provides a multi-quarter buffer to fund commercialization, R&D and payer access initiatives without immediate financing. This reduces execution risk and enables strategic investment while supporting working-capital needs during reimbursement timing.
Material Payer Wins Improving Market AccessSecuring major in‑network contracts expands covered lives and should raise realized ASPs and reduce collection friction. Durable payer relationships support steady revenue per test and competitive positioning, helping embed BillionToOne into standard clinical pathways over the medium term.
Bears Say
Dependence On Medicare Reimbursement For Oncology MarginsOncology profitability materially depends on favorable Medicare coverage; absent timely approval, oncology ASPs and margins may remain depressed as volumes scale. This creates a structural execution and reimbursement risk that could persist for multiple quarters or years if coverage timelines slip.
Revenue Recognition And AR Timing VolatilityTrue‑ups and AR buildup from new contracts create recurring quarter‑to‑quarter recognition and cash timing volatility. Structural unpredictability in billing/collection complicates forecasting, can distort reported growth and temporarily strains operations despite strong underlying demand.
Returns And Margin Still Thin Despite ImprovementAlthough margins improved, low net margin and ROE indicate limited earnings power relative to the balance sheet. This leaves results vulnerable to cost re‑expansion, mix shifts toward lower‑margin oncology, or pricing pressures, requiring sustained margin discipline to convert growth into durable shareholder returns.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $138.70 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $4.65B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Dec 15, 2026 which is in 183 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on May 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.309.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,442,833 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.34 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 14.128%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.33 (60.17% Upside)
$123.33 (60.17% Upside)
Blogger Sentiment
Bullish
BLLN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $944.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance: very high revenue and volume growth (84% and 44% YoY), expanded ASPs and gross margins (73%), attainment of GAAP profitability and positive cash, major payer wins (Anthem, United), and notable product innovation (Unity Confirm, MRD roadmap). Primary risks noted were margin pressure as oncology scales without Medicare coverage, timing/recognition volatility from true-ups and AR, and multi-year clinical and reimbursement timelines for certain products. On balance, the positives (robust growth, profitability, payer access, new product launches, upgraded guidance, strong cash position) materially outweigh the operational and timing risks cited.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$123.33
▲(60.17% Upside)
Ownership Overview
7.80% Insiders
6.65% Mutual Funds
17.10% Other Institutional Investors
67.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---